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Abstract
The liver fluke Fasciola hepatica is a parasite of ruminants with a worldwide distribution and an apparent increasing
incidence in EU member states. Effective control in dairy cattle is hampered by the lack of flukicides with a zero-withdrawal
time for milk, leaving the dry period as the only time that preventive treatment can be applied. Here, we present the results
of a blinded, randomized and placebo-controlled trial on 11 dairy herds (402 animals) exposed to F. hepatica to 1) assess the
effect of closantel treatment at dry-off (or 80–42 days before calving in first-calving heifers) on milk production parameters
and 2) evaluate if a number of easy-to-use animal parameters is related to the milk production response after treatment.
Closantel treatment resulted in a noticeable decrease of anti-F. hepatica antibody levels from 3–6 months after treatment
onwards, a higher peak production (1.06 kg) and a slightly higher persistence (9%) of the lactation, resulting in a 305-day
milk production increase of 303 kg. No effects of anthelmintic treatment were found on the average protein and fat content
of the milk. Milk production responses after treatment were poor in meagre animals and clinically relevant higher milk
production responses were observed in first-lactation animals and in cows with a high (0.3–0.5 optical density ratio (ODR)),
but not a very high ($0.5 ODR) F. hepatica ELISA result on a milk sample from the previous lactation. We conclude that in
dairy herds exposed to F. hepatica, flukicide treatment at dry-off is a useful strategy to reduce levels of exposure and
increase milk production in the subsequent lactation. Moreover, the results suggest that treatment approaches that only
target selected animals within a herd can be developed based on easy-to-use parameters.
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Introduction
The liver fluke Fasciola hepatica is a parasite of cattle and sheep
with a worldwide distribution. The infection is transmitted by
freshwater snails of the family Lymnaeidae. In Europe, the
principal intermediate host for F. hepatica is the amphibious snail
Galba truncatula. Under optimal conditions, it takes 6 weeks before
an infected snail starts to shed infective cercariae. These cercariae
encyst to metacercariae on grass, which are ingested by the final
host during grazing. Within the cow, it takes approximately 12
weeks for the parasite to mature to the adult stage and produce
eggs that are released via the cow’s faeces on pasture [1]. In
western Europe, the main period where cattle acquire new
infections is the autumn [2].
Because the completion of the life cycle depends on the presence
of suitable habitats for the intermediate host, the disease is
characterized by a focal distribution [3,4]. Nonetheless, herd-level
prevalences in cattle of 30% to 80% are commonly encountered
across Western Europe [5,6,7]. Moreover, several studies report
increasing incidences of fasciolosis in EU member states and this
trend has been primarily attributed to climatic changes, supporting
the overwintering of the intermediate host and of the metacer-
cariae [7,8,9,10].
Fasciolosis in cattle is generally subclinical and the negative
impact of infections on milk yield is well accepted [11].
Nonetheless, already in 1987 Dargie expressed his concern on
the lack of studies to quantify this effect [12]. Very few properly
controlled trials to assess the impact of flukicide treatment on milk
yield were conducted since then. With the abolition of the E.U.
milk quota regulations in 2015, European dairy producers face a
future situation with more volatile output prices and competition
[13]. In this context, quantification of the production impact of
enzootic animal diseases and their control measures is crucial for
supporting managerial decisions.
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Traditionally, the anthelmintic control of fasciolosis is based on
whole-herd treatments with flukicides during the winter period.
These treatment schemes have been recommended because most
flukicides only have a good activity against the adult stages of F.
hepatica, which are present during the winter period [14,15].
However, with the disappearance of flukicides with a zero-
withdrawal time for milk in most EU member states, such
treatment schemes are no longer economically justifiable and the
only period when flukicides can still be administered in lactating
animals is during the dry period [16]. To date, no studies are
available that evaluate the efficacy or impact on production of
flukicide treatment during the dry period. Only few flukicides are
registered for use in cows whose milk is used for human
consumption, but recently the European Medicines Agency
(EMA) recommended a provisional maximum residue limit
(MRL) for closantel in milk of bovine and ovine species (EMA/
CVMP/846853/2011) to avoid the creation of a therapeutic
vacuum.
The objectives of this study were 1) to assess the effect of
closantel treatment at dry-off on milk production parameters using
a randomized and placebo-controlled study and 2) to evaluate if a
number of easy-to-use animal parameters is related to the
production response after treatment, allowing a more selective
use of flukicides in the future.
Materials and Methods
Farm selection criteria
The study was conducted on 12 dairy herds located in Flanders
(Belgium). The herds were selected based on the following criteria:
(a) herds were naturally exposed to F. hepatica based on bulk tank
milk ELISA result ($0.8 optical density ratio (ODR)) indicative for
economic losses induced by the infection [6] at the beginning of
the trial (September 2010); (b) the animals involved did not receive
flukicide treatment #6 months before the experimental treatment;
(c) application of an average dry period $42 days in order to
respect the provisional withdrawal period for milk of closantel and
(d) storage of herd information and production data in
UNIFORM-Agri software (Assen, The Netherlands) enabling
standardized collection of the data.
Study design
This study was a blinded, randomized and controlled clinical
trial evaluating the effect of treatment with closantel on milk
production parameters and anti-F. hepatica antibody levels in milk
samples. Animals were drenched with closantel 5% oral solution
(SeponverH, Elanco Animal Health) or a placebo (the vehicle
liquid of the drug without the active compound) at a dosage of
0.2 ml per kg bodyweight at dry-off. First-calf heifers were
drenched between 80 and 42 days before the expected calving
date. The active compound and the placebo were dispensed in
identical bottles, uniquely labelled with a study and letter code.
Nor the farmer, nor the herd veterinarian, nor the principle
investigator (JC) knew which letter code corresponded to the active
product or placebo. The key was stored at Janssen Animal Health
(now Elanco Animal Health) and only revealed after data-analysis.
Treatments (closantel/placebo) were randomly assigned ac-
cording to Taves’ minimization method [17] assuring a propor-
tional assignment of the treatments within herd, infection level
(based on pre-treatment F. hepatica ELISA result), lactation number
and production level.
The study was approved by the Federal Agency for Medicines
and Health Products of Belgium, provided a provisional
withdrawal time for milk of 42 days was respected (File number
09 VN 1617).
On farm measurements
The treatment assignments were communicated to the farmer
through a hard copy list mentioning cow identification, expected
calving date, target date of experimental treatment administration
and treatment code. Treatments were performed by the farmer
based on estimated bodyweight. At timing of treatment, the farmer
was requested to complete the hard copy list with the body
condition score (BCS) (according to [18]), estimated bodyweight,
administered dose and date of treatment. The progress and
compliance to the study was monitored through monthly
telephonic contacts and three-monthly farm visits by the principal
investigator.
Collection of milk samples and Fasciola hepatica milk
ELISA
Bulk tank milk samples were collected with monthly intervals
from the beginning of the study (September 2010) until July 2011.
Individual milk samples from all lactating animals were collected
with three-monthly intervals from July 2010 onwards. The
samplings occurred as part of the routine samplings for quality
control and milk production registration programmes in cooper-
ation with Milk Control Centre Flanders (Lier, Belgium) and CRV
(Arnhem, The Netherlands). The samples were immediately kept
on ice during transport and stored at 220uC in the laboratory
until analysis.
The collected milk samples were subjected to a F. hepatica
ELISA as previously described [19]. This ELISA quantifies IgG
antibodies binding to the excretory-secretory products of F. hepatica
and the test results are expressed as ODR. The ELISA is based on
the protocol as described by Salimi-Bejestani et al. [20] who
reported a sensitivity and specificity when compared to serum
ELISA results of 92% and 88%, respectively. The sensitivity and
specificity of the ELISA applied on serum when compared to
worm counts was estimated at 87% and 90%, respectively [21].
Animals with an ODR$0.30 are considered positive for F. hepatica.
In our study, the aim was to evaluate whether F. hepatica ELISA
applied on individual milk samples in the previous lactation could
be used to identify which animals would benefit most in terms of
production responses to anthelmintic treatment.
Collection of production records and data processing
Production records from the participating herds were extracted
from the Dairy Data Warehouse (UNIFORM-Agri, Assen, The
Netherlands). The extracted variables were: kg milk, fat concen-
tration (g/kg), protein concentration (g/kg), somatic cell count
(SCC)/1000, breed, days in milk and lactation number. Depend-
ing on the production registration programme of the farm, milk
production records were recorded on a daily, 4-weekly or 6-weekly
basis.
Next, the milk production records were subjected to the
MilkBotH lactation model (DairySight LLC, Argyle, New York)
in order to obtain one aggregate measure of 305 day-milk
production per cow lactation. This lactation model is designed for
detecting and quantifying effects of disease or management
interventions on milk production. The functional form of the
MilkBotH lactation model was described by Ehrlich [22]. The
model has been previously used to assess the effect of metabolic
diseases on milk production [23] and demonstrated higher
accuracy and precision than the current dairy herd improvement
associations’ method for calculating lactation yields in the United
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States [24]. The model quantifies both the shape and magnitude of
lactation curves as a set of parameter values, each of which is
associated with a single aspect of lactation curve shape. The
parameter ‘‘scale’’ is a measure of magnitude, without changing
the shape of the curve. The parameter ‘‘ramp’’ measures the
steepness of the post-parturient rise in production. The parameter
‘‘decay’’ is used to measure the rate of decline in production after
the peak in milk production. Lactation curve analysis allows
detecting changes in the distribution of production that are not
apparent when only totals are analyzed.
Statistical data-analysis
The effect of closantel treatment on anti-F. hepatica antibody
levels in individual milk samples was investigated by a linear mixed
model with herd and cow as random effects and treatment
(closantel/placebo), days after treatment and an interaction term
between treatment and days after treatment as fixed effects.
Because the herds were sampled at 3-monthly intervals, the
variable ‘days after treatment’ was categorized in 3 intervals: ‘0–3
months’, ‘3–6 months’, ‘.6 months’.
The effect of closantel treatment on milk production parameters
was investigated by a linear mixed model with the production
parameter as outcome variable, herd as random effect and
treatment (closantel/placebo) as fixed effect. Lactation number
(‘1st’, ‘2nd’, ‘3rd or higher’), breed and the natural logarithm of
SCC/1000 were introduced as additional fixed effects because
they were considered as potential confounding factors. One herd
was excluded from the analysis because no SCC data were
available. In addition, two cows with breed Brown Swiss and one
with breed Friesian Red and White were removed from the
analysis because they all belonged to the closantel group without
counter parts in the placebo group. The evaluated production
parameters were (predicted) 305 day milk production, the different
lactation curve parameters (scale, ramp, decay), average fat
content (g/kg), average protein content (g/kg) and Ln(SCC/
1000). Cows were only included in the analysis if at least 3 separate
production records over a time period of .3 months were
available.
The relationship of animal parameters with the production
response after treatment was evaluated using the model to estimate
the effect of treatment of 305-day milk production. Continuous
potential decision parameters (anti-F. hepatica antibody level and
BCS) were categorized according to their quartiles. If more than
one anti-F. hepatica antibody measurement was available pre-
treatment, the average value was used for categorization. The
treatment effect was estimated within each category of the pre-
treatment anti-F. hepatica antibody level, BCS centred to the herd
mean, year quarter of treatment and lactation number.
All statistical analyses were carried out with the PROC MIXED
command in the software package SAS version 9.3 (SAS institute
Inc., Cary, NC, USA). Normality of the residuals was checked by
Q-Q plots. Heteroscedasticity was checked by plots of the residuals
vs. predicted values. Additional diagnostic plots were performed to
assess independence of the residuals and linearity of the means.
Variance component estimation was based on restricted maximum
likelihood and statistical significance of fixed effects was based on
F-statistics.
Results
Herd characteristics before treatment and treatment
allocation
Treatment records and ELISA results to analyse the effect of
treatment on anti-F. hepatica antibody levels were available for 475
cows from 12 herds. The closantel and placebo group in this
analysis consisted of 246 and 229 animals, respectively. The
average anti-F. hepatica antibody level in individual milk samples in
the period before treatment administration was similar in both
treatment groups (Table 1).
The analysis of the effect of treatment on milk production
parameters was based on data from 402 cows from 11 herds.
Table 1 shows the characteristics of the cows included in the
analysis of the effect of treatment on milk production parameters:
the 305-day milk production in the period before treatment was
similar and the number of cows in the treatment groups, parity,
breed and year quarter in which the treatment was performed was
evenly distributed between the 2 treatment groups, indicating a
successful treatment allocation.
Anti-Fasciola hepatica antibody levels in milk
The course of anti-F. hepatica antibody levels in bulk-tank milk
during the study period is shown in Fig. 1A. Two months after the
start of the trial, the mean bulk-tank milk antibody level showed a
substantial decrease and subsequently remained at a more or less
stable level. The course of anti-F. hepatica antibody levels in
individual milk samples relative to the time post-treatment is
shown Fig. 1B. The anti-F. hepatica antibody levels decreased after
treatment in both the closantel and the placebo-group (P,0.001)
with significantly lower antibody levels in the closantel group than
in the placebo group (P=0.05). The interaction term between
treatment and days after treatment was not significant (P=0.11).
The proportion of the total variation in anti-F. hepatica antibody
levels that resided at the herd, cow and residual level was 7, 51 and
42% respectively, indicating that there was a great variation in
anti-F. hepatica antibody levels between cows within a herd.
Table 1. Number of cows, average 6 standard deviation of
anti-F. hepatica antibody levels before treatment and 305-day
milk production in the lactation before treatment and
distribution of breed, parity and year quarter of treatment in
the 2 treatment groups.
Parameter Closantel Placebo
Nu of cows 208 194
Anti-F. hepatica antibody level (ODR) 0.3660.26 0.4060.27
305-day milk production (kg) 9,01261,661 9,05961,742
Breed:
Holstein Friesian 45.3 43.0
Dutch Friesian 6.5 5.2
Parity (%):
1st 11.2 10.5
2nd 16.7 13.7
$3rd 23.9 24.1
Year quarter:
Jan–Mar 12.4 11.9
Apr–Jun 5.2 4.7
Jul–Sep 16.9 15.7
Oct–Dec 17.2 15.9
doi:10.1371/journal.pone.0043216.t001
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Overall treatment effect on milk production
The results of the linear mixed model to evaluate the effect of
closantel treatment on 305-day milk production are given in
Table 2. After controlling for the factors lactation number, breed
and somatic cell count, the 305-day milk production in the
closantel group was increased by 303 kg (P=0.026), which
corresponds to a milk production response of 0.99 kg/day per
cow. No significant effects of anthelmintic treatment were found
on the average protein (P=0.93) and fat content (P=0.58) of the
milk produced or on somatic cell counts (P=0.45). Least square
means of these variables in both treatment groups are given in
Table 3. Finally, the MilkBotH parameters (scale, ramp, decay) in
Table 3 and the resulting lactation curve in Fig. 2 show how the
shape of the lactation curve was modified by treatment. The
results suggest that closantel treatment resulted in a higher peak
production and a slightly higher persistence (9%) of the lactation.
The relationship between animal parameters and the
milk yield response after anthelmintic treatment
The effect of closantel treatment on milk production according
to several potential decision parameters is given in Fig. 3. The
highest treatment effect was found in cows with a pre-treatment F.
hepatica ELISA result between 0.30 and 0.48 ODR (3rd quartile). In
this category, the 305-day milk production was increased by
823 kg (95% confidence interval: 164, 1482). No treatment effect
was observed in the highest F. hepatica ODR category (4th quartile).
Other potential trends were greater milk production responses
after closantel treatment in cows with increasing BCS, in cows
treated during the third year quarter and in first-lactation cows.
However, the 95%-confidence intervals of these categories all
included 0.
Discussion
To our knowledge, this is the first blinded, randomized placebo-
controlled study on the effect of fasciolicide treatment on milk
yield. Previous studies only investigated associations between F.
hepatica infection status and milk yield [19,25], or assessed the effect
of chemotherapy but lacked a placebo-administered control group,
randomization and follow-up during a whole lactation [26,27,28].
The anthelmintic treatments and the recording of potential
decision parameters were performed by the farmers, therefore
the results of this study are considered repeatable under field
circumstances.
Previously, we showed that an increase in the anti-F. hepatica
level in bulk tank milk over the interquartile range was associated
with a drop in the annual average milk yield of 3% [19]. Here, we
show that these losses are to a large extent recoverable by
anthelmintic treatment. Closantel treatment at dry-off resulted in a
3.3% increase in milk yield (1 kg/cow per day) in the subsequent
lactation. This effect was mainly due to a better start-off of the
lactation with a steeper rise in production and a higher peak
production, suggesting it is induced by an improved liver
metabolism post-partum. The observed effect of 3.3% increase
in milk yield is considerably lower than in previous studies where
milk production responses up to 8 and 15% after flukicide
treatment are reported [26,27]. However, these authors failed to
monitor milk production over a whole lactation and such
production responses may thus be realistic on a short term or in
individual animals as observed here in animals with a F. hepatica
ODR between 0.3 and 0.5, but not on an average basis.
Nonetheless, compared with the cost of an anthelmintic dose, a
treatment response of 3.3% increase in milk yield represents
approximately a 10-fold return on investment [29].
Figure 1. The course of anti-F. hepatica antibody levels (ODR)
during the study period in bulk-tank milk samples from the 12
studied herds (A) and relative to the months after experimen-
tal treatment in individual milk samples of 475 cows in the 12
herds (B). Bars represent standard error of the mean.
doi:10.1371/journal.pone.0043216.g001
Figure 2. The average lactation curve of cows following
treatment with closantel or a placebo at dry-off (Curves
represent the data for Holstein Friesian cows in$3rd lactation).
doi:10.1371/journal.pone.0043216.g002
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In contrast to previous studies, we could not observe an effect of
flukicide treatment on the fat content of the milk [28,30]. Because
we investigated the effect of treatment on the average fat
concentration over the whole lactation, such effect may still have
been present on a short term after treatment, which was not
detectable in our analysis.
We must recognize that probably not all of the observed effects
on milk yield can be ascribed to reduction in the F. hepatica burden.
Closantel is also active against other blood-feeding parasites of
cattle such as Haemonchus spp. and Hypoderma bovis [31]. However,
the prevalence of these parasites in dairy cows in the study area is
low [32,33,34]. Moreover, the significant drop in anti-F. hepatica
levels post-treatment suggests that the majority of the effect of
closantel treatment on milk yield is caused by its activity against F.
hepatica.
As reported in other studies [35,36], the difference in anti-F.
hepatica antibody level between the 2 treatment groups could only
be clearly observed .3 months post-treatment. The significant
drop in anti-F. hepatica antibody levels suggests that treatment at
dry-off resulted in a successful reduction of the worm burden, even
if these treatments were applied throughout the year when
immature stages of F. hepatica are present. Closantel has only a
partial activity against immature stages (,9 weeks old) of F. hepatica
in the cow [15,37]. However, in our study the population of
immature stages may have been small. This is suggested by the
decrease in anti-F. hepatica antibody levels that was observed in the
placebo-treated animals and in the bulk-tank milk during the
study. Low levels of reinfection may be attributed to the treatment
of part of the herd and the climatic conditions that were
considered unfavourable for the development of free-living stages
of F. hepatica during the study period (2010–2011) (Based on the
reports of the Prognosis Commission on liver fluke of the
Netherlands; L. Moll, personal communication).
It is of major concern to food safety organisations and dairy
cooperatives to prevent the presence of medicine residues above
the MRL in commercialized milk. Selective use of flukicides will
therefore become of increasing importance to reduce the
consumer’s risk of exposure to residues in milk. Moreover,
selective use of anthelmintics is considered to reduce the
development of anthelmintic resistance [38]. In this context,
treatment at dry-off where only few individuals are treated at a
given moment is a safer strategy than the traditional whole-herd
treatments. Moreover, our results suggest that it is possible to
identify animals within a herd that will benefit most from
anthelmintic treatment by easy-to use animal parameters, thus
enabling a more selective use of anthelmintics. The animal
parameters were evaluated based on a randomized study.
Therefore, observed differences are likely to have a causal
relationship with the treatment.
Clinically relevant higher production responses after treatment
were observed in animals with a pre-treatment ODR between 0.3
to 0.5, in animals with a higher BCS at dry-off (3rd quartile), in
first-lactating animals and treatments administered in the 3rd year
quarter. Higher treatment responses in the 3rd year quarter may
be explained by the fact that this was in the beginning of the trial
when the levels of infection were considered highest (see discussion
above). Higher treatment responses in animals with a pre-
treatment ODR .0.3 could be expected because animals above
this threshold are considered infected with F. hepatica. However,
the lack of milk yield response after treatment in the highest pre-
treatment ODR category (0.5–1.5) is striking. There is no reason
Table 2. The results of a linear mixed model to estimate the effect of closantel treatment at dry-off (or approximately 42 days
before calving for heifers) on 305-day milk production in 11 herds exposed to F. hepatica (based on 402 cows).
Variable b S.E. P
Intercept 10,685 544 ,0.001
Closantel (vs. placebo) 303 135 0.026
Lactation number (baseline = 3rd and higher): ,0.001
First 22,522 189
Second 2543 163
Breed (baseline =Holstein Friesian):
Dutch Friesian 2256 259 0.324
Ln (SCCa/1000) 2158 61 0.009
Random effects Variance S.E.
Proportion of total
variance (%)
Herd 2,007,621 924,635 53
Residual 1,812,943 130,498 47
aSomatic cell count.
doi:10.1371/journal.pone.0043216.t002
Table 3. Least square meansa (standard error of the mean) of
average protein and fat concentration and milk production
parameters following treatment in the closantel and placebo
group.
Variable Closantel Placebo P
Average protein content (g/kg) 31.8 (0.6) 31.8 (0.6) 0.93
Average fat content (g/kg) 38.7 (0.9) 38.4 (0.9) 0.58
Ln (SCCb/1000) 5.05 (0.15) 4.96 (0.15) 0.45
Scale 43.59 (2.26) 42.53 (2.27) 0.14
Ramp 24.98 (0.89) 23.69 (0.91) 0.05
Decay 0.0022 (0.00009) 0.0024 (0.00009) 0.10
P-values evaluate the difference between the 2 treatment groups.
aLeast square means for Holstein Friesian Cows in $3rd lactation.
bSomatic cell count.
doi:10.1371/journal.pone.0043216.t003
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to believe that this is related to lack of anthelmintic efficacy.
However, it has been shown that F. hepatica ODR is correlated
with infection intensity and extent of liver pathology [21,39,40]
suggesting that remaining liver pathology after treatment prevent-
ed the occurrence of a clear production response in these animals.
This was also suggested as the reason for lack of production
response in retired dairy cows where closantel treatment efficiently
removed the worm burden, but did not induce increased weight
gain [41]. Alternatively, lack of production responses in very high-
ODR animals could also be caused by a-specific reactions in the F.
hepatica ELISA such as those that can occur in milk samples from
mastitis-affected udders [42]. The observed relationship between
BCS and milk yield response after treatment appears highly similar
as the documented quadratic relationship between BCS around
partus and subsequent milk production with an optimum milk
production in cows with a BCS (on a 5-point scale) of 3.5 [43]. In
our study poor production responses were observed in animals in
the first and second quartile of BCS and highest production
responses in animals in the third quartile of BCS. The greater milk
yield with increasing BCS to an optimum is considered to be the
result of a greater availability of energy for the cow. By
comparison, the reduction in milk yield when the optimum
calving BCS is surpassed is considered as the result of lower dry-
matter intake in overconditioned cows [43]. BCS may thus be an
important parameter for selective flukicide treatment, but our
study did not look into potential weight gain responses after
treatment in low BCS animals. Finally, the higher treatment
responses in 1st lactation animals can be explained by the typical
different quality of pastures grazed by heifers compared to milking
cows. The better pastures are typically preserved for the milking
cows; heifer pastures being more humid and displaying more
vegetation diversity thus exhibiting a greater transmission potential
for F. hepatica infection [4,44].
In conclusion, in this randomized controlled field study, we
demonstrated that in dairy herds exposed to F. hepatica, closantel
treatment at dry-off is a useful strategy to reduce the levels of
infection with F. hepatica and increase milk production in the
subsequent lactation. Production responses were highest in first-
lactating animals and in animals with a high (0.3–0.5 ODR), but
not very high (.0.5 ODR) anti-F. hepatica antibody level in pre-
treatment milk samples, while they remained poor in meagre
animals. We propose to use age and anti-F. hepatica antibody level
in pre-treatment milk samples as easy-to-use animal parameters
for selective treatment within a herd. This will likely reduce the
risk of unwanted flukicide residues in milk. Further research is
required to assess the economic impact of our findings and of
selective treatment approaches.
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